99% Invisible cover image

Orphan Drugs

99% Invisible

00:00

Industry Defense: High Costs and High Risk

Joshua Schein's perspective: rare-disease drug development is costly and risky, justifying incentives and returns.

Play episode from 20:56
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app